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ABSTRACT
Antibiotic resistance surveys are published widely, citing percentage resistance rates, sometimes for vast
transcontinental regions. Such data seem straightforward, but when one drills deeper, great complexity
emerges. Rates for methicillin resistance among Staphylococcus aureus from bacteraemias vary from <1%
to 50% among European countries, and vary greatly among both hospitals and hospital units.
Methicillin-resistant S. aureus (MRSA) resistance rates are typically higher for tertiary-care hospitals and
intensive care units than in general hospitals and wards, and lowest in single specialist centres. The
likelihood of resistance also varies according to patient characteristics: those patients from nursing
homes and with underlying disease, recent antibiotic treatment and hospitalisation are more likely to
harbour resistant pathogens. Percentage rates themselves also may be misleading; they may be high
only because the denominator is small or inaccurate; i.e., resistance may be common but the pathogen
rare. Measures of disease burden—cases per 1000 bed-days or per 105 individuals—overcome this
deficiency but are harder to collect, influenced by case mix, and associated with other problems: how to
count part days or infections acquired elsewhere; most important, are all cases captured? National or
international resistance statistics may illustrate trends and provide benchmarks, but for patient
management, good local data are essential. Which units are most affected? Are the resistant infections
locally acquired or imported with transferred patients? Are the resistant isolates clonal, indicating cross-
infection, or diverse, indicating repeated selection or reflecting antibiotic policy? Unless these aspects of
infection are considered, interventions to reduce resistance may be misdirected.
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INTRODUCTION
Antibiotic resistance varies with time and place.
On the ‘macro’ level, it varies among countries,
with occasional paradigm shifts as new resistance
types proliferate. At the ‘micro’ level, antibiotic
resistance varies among units within a hospital
and among patient groups. This article seeks to
illustrate these differences, highlighting the need
for good local surveillance as well as for broad
national data. The national data show secular
trends, while local data underpin antibiotic poli-
cies, infection control, and empirical antibiotic
choices. We aim also to highlight the cautions
necessary when reading and interpreting resist-
ance surveys. We do not seek to criticise these
surveys, for they remain the best source of data
available, and ‘perfect’ surveillance is prohibi-
tively expensive; rather, we try to help the reader
navigate around the potholes.
It should be noted, first of all, that practically all
surveillance of resistance considers only those
isolates routinely submitted to microbiology labor-
atories. Bacterial culture and susceptibility testing
is generally undertaken for severe infections in
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hospitals; for community infections, however, it is
biased towards complex cases, potentially over-
estimating the extent of resistance [1]. Around
50% of community urinary infections receive
microbiological investigation in the UK; however,
for respiratory infections [2], the rate falls to 3%.
Moreover, individual general practitioners vary
greatly in their propensity to submit specimens
for culture and susceptibility testing. For urine
cultures, the UK submission rate ranges from 29
to 296 samples per 1000 registered patients per
annum [3], and many practitioners submit sam-
ples only from those patients who are responding
poorly to empirical treatment—perhaps because
their infection was caused by a resistant strain.
Evidently, these form a biased sample.
Insight into the extent of this distortion is
provided by a recent study of uncomplicated
cystitis in Norwich and Gloucester (UK), which
sampled consecutive patients on the basis of
clinical symptoms and found a trimethoprim
resistance rate of 13.9%, compared with rates of
24–27% among urinary isolates routinely submit-
ted to the two laboratories [4]. More notoriously,
penicillin-resistant pneumococci are well-repre-
sented in many resistance surveys but prove
remarkably scarce when consecutive patients in
the same regions are recruited for prospective
antibiotic trials. It is not clear whether this is
because the surveys overestimate resistance, ow-
ing to sample bias, or because the trials mostly
exclude those complex, frequently treated pa-
tients who are most likely to harbour resistant
bacteria. All resistance surveys, but particularly
those of community pathogens, should be read
with these caveats in mind.
VARIATION BY COUNTRY
Several large international programmes undertake
surveillance of resistance, or have done so until
recently. These include SENTRY [5], PROTEKT [6],
SMART [7], MYSTIC [8], and the Alexander Pro-
gramme (http://www.alexandernetwork.com),
all with high-quality microbiological data. Their
results illustrate gross trends, but the programmes
have only a handful of collecting sites per country,
and these are often major teaching or tertiary-care
centres, potentially creating sample bias, since
these hospitals tend to manage the most complex
patients (see below). The number of isolates sam-
pled per annum is fewer than 10 000 in all of these
surveys and, as with political opinion polls, it is
remarkable that the results often agree so well, or
show so little year-to-year fluctuation!
What is more, surveys often present results for
huge geographical regions, e.g., Europe or the
Western Pacific (meaning East Asia, Australia and
Oceania), which include a great diversity of
countries and peoples, varying greatly in how
their medical systems are organised, in their
control of public access to antibiotics, and in the
emphasis they may give to hospital infection
control. Major differences emerge if one drills
deeper, using surveys that consider only single
regions, and with numerous collection sites (e.g.,
http://www.earss.rivm.nl or http://www.bsac-
surv.org). As is well-known, the proportion of
methicillin-resistant Staphylococcus aureus (MRSA)
among S. aureus isolates from patients with bac-
teraemia is much lower in Scandinavia and The
Netherlands than elsewhere in Europe [9]
(Table 1). Other examples are that MRSA is less
prevalent in Canada than the USA [10], and that,
within the Western Pacific region of, for example,
the SMART programme, numerous resistances
among Gram-negative bacteria are less prevalent
in New Zealand and Australia than in China or
Southeast Asia [11].
The high MRSA rates in southern Europe, the
UK and Ireland are relatively stable, having
persisted at 30–40% for at least 5 years, whereas
the now-high rates in much of central Europe
have been rising steeply in the same period
(http://www.earss.rivm.nl). The low Scandina-
vian and Dutch rates reflect extremely stringent
‘search and destroy’ infection control policies
which quarantine high-risk hospital admissions
(e.g., those from other countries or with suspected
MRSA contact) until they have been proven not to
be carriers. When MRSA infections do occur, the
Dutch and Scandinavians put emphasis on erad-
ication from any contacts who may have become
colonised or infected [12]. Where necessary, con-
taminated wards are closed and deep-cleaned.
Such policies work, although they may be prac-
ticable only when MRSA rates are low. Elsewhere
in Europe (and in most of the rest of the world),
MRSA rates have crept above some still unde-
fined threshold where, given bed-pressure,
‘search and destroy’ has become impracticable
[13]. The alternatives adopted—pre-admission
screening for elective admissions, surveillance
cultures, continual re-emphasis of hand hygiene,
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contact precautions, and use of side rooms or
separate wards to isolate and cohort infected or
colonised patients—have proved far less effective
than the stringent Dutch and Scandinavian meth-
ods, although it is debatable to what extent the
failures reflect inadequacy of the procedures or
their not having being enforced with sufficient
single-mindedness in a world of competing pri-
orities and targets [14].
In the case of pneumococci from bacteraemias,
there is a remarkable linearity across Europe
between the density of outpatient prescribing of
penicillins and the prevalence of resistance [15]
(figure 1), both of which are higher in the south
than in the north [16] or, more precisely- for the
rates in Ireland and Poland are high too- in
traditionally Catholic Europe than in Protestant.
This geographic split is counter-intuitive, for one
would expect less prescribing in the south-with
its warmer, drier climate, less conducive to
respiratory illness. Is the cultural heritage of the
Reformation, which redefined relationships
between individuals and higher authority, some-
how still reflected, in a largely secular age, in
cultural propensity to seek medical intervention
for respiratory infections? These may seem wild
and provocative speculations, but were the con-
clusions of one study, comparing Middleburg in
the Netherlands (historically largely Protestant)
with Bruges, 60 km away in Belgian Flanders
(speaking the same language but Catholic) [17]
(Table 1). Whether one accepts the relationship to
cultural background or not (and we advocate
caution, for the samples are small), upper
respiratory tract infections were largely termed
‘‘colds’’ or ‘‘flu’’ by the Dutch, who nursed
themselves, but ‘‘bronchitis’’ by the Belgians,
who sought medical attention and received
antibiotics (Table 2).
INTERPRETING PERCENTAGE
RESISTANCE RATES FROM SURVEYS
It should be added that the percentage resistance
rates, as routinely published for surveys and
widely cited, potentially give a distorted picture.
A rate may be high while the incidence of
infection is low. Some of the highest percentage
rates published are for resistance in Enterococcus
faecium and Acinetobacter baumannii, but infections
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Fig. 1. Relationship between community penicillin usage
in defined daily doses and penicillin resistance (expressed
as the natural logarithm of the probability of resistance in
any given isolate) among pneumococci from bacteraemia
in different European countries, 2005; reproduced from
Bronzwaer et al. [15] with permission. Codes are: NL, The
Netherlands; DK, Denmark; SW, Sweden; FI, Finland; UK,
United Kingdom; LU, Luxembourg; IE, Ireland; BE, Bel-
gium; IT, Italy; PT, Portugal; ES, Spain.
Table 1. Methicillin-resistant Staphylococcus aureus (MRSA)
bacteraemia rates across Europe, based on EARSS data for
2004 [22]
Country
MRSA as
% S. aureus
MRSA bacteraemias
per 105 bed days
Iceland 0 <0.96
Norway <1 0.12
Sweden <1 0.26
Denmark 1 No data
Netherlands 1 0.35
Finland 3 0.8
Estonia 5 0.34
Czech Republic 9 1.02
Slovenia 12 2.04
Austria 14 No data
Luxembourg 16 No data
Hungary 17 1.27
Germany 19 3.29
Slovakia 19 2.00
Poland 20 1.12
Bulgaria 24 1.53
Latvia 25 1.72
Spain 26 6.00
France 29 11.79
Belgium 33 7.75
Croatia 38 6.14
Israel 39 12.16
Italy 40 6.44
Ireland 41 12.02
Greece 44 7.36
UK 44 9.56
Portugal 46 17.58
Cyprus 49 7.91
Malta 56 19.29
Romania 73 1.92
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with these pathogens are 10- to 100-fold less
frequent than those with S. aureus and Escherichia
coli [18]. Multiresistance in E. coli and S. aureus is
therefore the greater concern, and assertions that
‘Acinetobacter is the new MRSA’ are exaggerated
[19].
Epidemiologists justifiably argue that it is better
to cite rates of resistant infection per 105 individ-
uals or per 1000 patient-days rather than to quote
percentages of resistant isolates, but the former
parameters are more difficult to capture and are
meaningful only if all cases of infection are
recorded. This is unlikely to be true unless
reporting is mandatory, as with bacteraemias
due to MRSA and vancomycin-resistant entero-
cocci in England [20]. Even then, the resulting
rates are distorted by the issue of how to count
part-days, which become a greater factor as
hospital stays become shorter. Moreover,
although an infection may manifest in a hospital,
it does not mean that it was contracted there. This
is critical for the mandatory MRSA bacteraemia
surveillance in the UK, where the rates are the
basis for defining MRSA reduction targets for
each hospital, but where 8% of MRSA bacterae-
mias are apparent at the time of hospital admis-
sion and a further 25% are manifest within 48 h of
admission, implying that the infection originated
elsewhere [21].
The EARSS report for 2004 [22] provides data
on MRSA bacteraemias per 1000 bed-days across
Europe. These incidence rates are much lower for
many east European countries than for west
European countries with comparable percentage
prevalence rates (Table 1). It seems likely that the
explanation is simply that blood cultures are done
less often in eastern Europe than in the west,
especially if the primary focus of the infection is
believed to lie elsewhere.
RATES OF RESISTANCE VS. UNIT
AND PATIENT TYPE
Within countries, there is great variation in
infection and resistance rates among different
hospital and patient types. The UK mandatory
surveillance for MRSA indicates a higher inci-
dence in teaching hospitals than in large acute-
care general hospitals, which, in turn, have higher
rates than small acute-care hospitals; the lowest
rates are for single-specialty trusts, e.g., those
specialising in ophthalmology or orthopaedic
surgery (Table 3). A similar relationship between
hospital size and MRSA prevalence rate exists in
the USA, where the National Nosocomial Infec-
tions Surveillance (NNIS), with approximately
300 participating sites, reported that the intensive
care units (ICUs) of major teaching hospitals had
significantly higher rates of infection than the
ICUs of all other reporting hospitals. This may be
because they handle more complex and vulner-
able patients, with longer lengths of stay and
greater exposure to known risk-factors for resist-
Table 2. Attitudes to antibiotics in Middleburg and
Bruges [17]
Survey sites
Bruges,
Belgium
Middleburg,
The
Netherlands
Language Flemish Flemish
Nature of town Prosperous,
non-industrial
Prosperous,
non-industrial
Cultural background Catholic Protestant
Survey participants
Total interviewed 15 15
Representing family
members (n)
36 33
Cases of upper
respiratory tract
infection reviewed
28 20
Patient’s description
‘Cold’ 4 9
‘Bronchitis’ 9 –
‘Flu’ – 5
‘Cough, runny nose’ 8 2
‘Sinusitis, angina’ 7 4
Patient’s action
Consulted doctor 14 (50%) 4 (20%)
Received antibiotics 11 (40%) 3 (15%)
Self-medicated 9 3
‘Nursing one’s illness’ 5 13
Table 3. Incidence rates for methicillin-resistant Staphylo-
coccus aureus bacteraemias in England by hospital type [21]
Cases per 10 000 bed-days
April–September
2001
October 2005
to March 2006
Acute teaching 2.38 1.99
Large acute 1.67 1.85
Medium acute 1.42 1.46
Small acute 1.27 1.54
Acute specialist,
children
0.83 0.97
Acute specialist 0.74 0.62
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ant infections, such as devices, lines and antibiotic
treatment [23]. Moreover, the uptrend in MRSA
infections through the 1980s and 1990s in the USA
was slower and came later in the smaller hospitals
[14].
Even discounting such factors, there is still
variation in MRSA bacteraemia rates when
ostensibly similar acute-care general hospitals in
England are compared with each other. Such
variation must partly reflect relative attention to
infection control and antibiotic usage patterns
[24], although the roles of quinolones and ce-
phalosporins in MRSA selection remain contro-
versial [25,26], and a recent study found little
correlation between visual cleanliness and the
incidence of MRSA bacteraemias [27]. The other
critical factor is case-mix: MRSA bacteraemias are
rare among maternity and psychiatric patients
and in infants, so that large units handling these
patients will ‘dilute’ a hospital’s rate, calculated
as cases per 1000 bed-days across the whole site
[21].
Resistance rates vary within hospitals too. The
USA’s NNIS system showed that resistance rates
for many pathogens were highest in isolates from
ICUs, lower in other inpatient groups, and lower
still among outpatient isolates [23].
Other US and European studies have also
identified ICUs as having a higher prevalence of
resistant organisms [28] than other hospital areas,
while mandatory surveillance reveals that a dis-
proportionately large number of MRSA bacterae-
mias in England occur in intensive care or
nephrology patients [21] (Figure 2).
Other patient groups in which multiresistant
organisms are disproportionately prevalent in-
clude those who receive multiple rounds of
treatment for intractable infections, e.g., cystic
fibrosis patients with Pseudomonas aeruginosa
infection [29]. The rates of resistance in these
patients are three to four times higher than among
the generality of P. aeruginosa isolates, and the
isolates are more often hyper-mutable, indicating
an increased potential to develop further resi-
stances [30].
E. coli presents another example of the rela-
tionship between resistance and patient type.
Rates of trimethoprim resistance are significantly
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Fig. 2. Numbers of MRSA bacter-
aemias, detected ‡48 h after admis-
sion, in English hospitals in relation
to (a) specialty and (b) augmented
care category. Codes are: Gen med,
general medicine; Gen sur, general
surgery; T & O, trauma and ortho-
paedics; Clin haem, clinical haema-
tology; Cardio sur, cardiothoracic
surgery; ICU, intensive care unit;
HDU, high-dependency unit;
Gastro, Gastrointestinal; Cardio,
cardiothoracic; CCU, critical care
unit; Neuro ICU, Neurosurgical
Intensive Care Unit; Post-op recov,
post-operative recovery unit. Data
are from [21], reproduced with
permission.
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increased among isolates from those cystitis
patients who have had multiple (‡4) courses of
trimethoprim in the preceding months [4,31],
while strains with quinolone resistance and
extended-spectrum b-lactamases are mostly
found in older patients with underlying disease,
recent antibiotic treatment, and a history of
hospitalisation [32,33]. By contrast, trimethoprim
resistance rates among isolates from uncompli-
cated cystitis patients are lower than those
among the generality of isolates submitted to
laboratories for culture and susceptibility testing
[4].
All these associations carry the implication that
the global resistance rates for a species, or even
for a species in a particular clinical setting, tell us
rather little about the risk of resistance in a
particular patient for whom empirical therapy
must be selected. Rather, the choice of empirical
treatment must also reflect the patient’s risk-
factors, and this demands not only a radical
improvement in the design and understanding of
local surveillance, but also better liaison between
the laboratory and the responsible clinicians than
is often the case at present.
OF STRAIN AND PLACE
Those resistances that evolve by easy mutation,
e.g., derepression of the chromosomal AmpC b-
lactamase in Enterobacter spp., are liable to be
selected repeatedly wherever selective pressure
by third-generation cephalosporins is exerted
[34,35]. Likewise, extended-spectrum mutants of
TEM and SHV b-lactamases could evolve on
many occasions and at many places, since their
parent enzyme types were widespread when the
selective third-generation cephalosporins were
introduced [36].
By contrast, those resistances that evolve only
rarely and do not transfer readily—e.g., methicil-
lin resistance in S. aureus or penicillin resistance
in pneumococci—disseminate by transfer of
strains among people, hospitals and countries.
The absence of such a resistance from a particular
locale may simply signify that potent, fit strains
with the corresponding mechanism have not yet
reached that location.
Within countries, resistant clones may remain
more or less confined, perhaps reflecting patterns
of hospital transfers. In London in the 1980s, the
MRSA problem, then due to EMRSA-1, affected
hospitals north of the River Thames, only gradu-
ally spreading south [37]. The now dominant
EMRSA-15 and EMRSA-16 strains emerged and
spread in the UK Midlands and south-east
[38,39], only gradually moving into northern
England and into Scotland. Even now, infections
with these (or any other MRSA strains) are very
uncommon in hospitals on the Hebrides and
Orkney Isles (Eastaway, Health Protection Scot-
land, personal communication). As a second
example, the UK currently has two prevalent
A. baumannii strains that are resistant to carbap-
enems: OXA-23 clone 1, and the SE (south-east)
clone. Each has been recovered at approximately
40 hospitals serving overlapping patient popula-
tions, mostly in London and south-eastern Eng-
land [40]; neither has yet spread to the Midlands
or the North, even 3–6 years after they were first
recorded. Carbapenem-resistant isolates from
more northerly cities are few in number and
are either clonally diverse or, if clonal, localised
to a few sites. Of the two major clones, the OXA-
23 clone is very susceptible to tigecycline, at least
in vitro, with MICs £0.25–0.5 mg ⁄L, as compared
to 1–2 mg ⁄L for the SE clone [40]; the clinical
significance of this observation remains to be
confirmed. In contrast, a carbapenem-resistant
Acinetobacter clone with the OXA-40 enzyme is
spreading in hospitals around Chicago and is
resistant also to tigecycline, with MICs mostly of
4–8 mg ⁄L [41]. It follows that one’s optimism
about tigecycline as an answer to ‘pan-resistant’
Acinetobacter is likely to be a function of strain
and location. It is currently striking; too, that
MRSA and extended-spectrum b-lactamases
(ESBLs) are evolving differently in the USA
and Europe. In Europe, MRSA remains largely
a nosocomial problem, with the prevalent strains
spreading via the hands of hospital personnel
[42]. Most infections occur in elderly patients
with underlying disease or those who become
contaminated as a result of surgery. Colonisa-
tion, but rarely infection, may spread within
nursing homes [43]; community-acquired infec-
tions remain rare, although there is concern
about the community-adapted ST80 lineage
[44]. In the USA, by contrast, the increasing
problem is with community-acquired MRSA
[45]. The newly emerged ST8 ⁄USA300 and
USA400 lineages responsible for these infections
are spread, in markedly younger age groups,
by close physical contact, as in sports, gay
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bathhouses, and prisons, and as a result of
sharing towels and other personal items [46,47].
ESBLs provide the mirror image of this epi-
demiology: the problem in Europe is increasingly
one of E. coli with CTX-M-type enzymes, often
causing infections that manifest in the community
or in nursing homes [48]. The pattern in the USA
remains one where most ESBLs are mutants of the
old TEM and SHV penicillinases, most often
produced by Klebsiella spp., just as was previously
the case in Europe. These differences are likely to
erode as the more successful strains become
globalised. There are already reports of the
American community MRSA strain USA300
in Europe [49] whilst E. coli strains with CTX-
M-15 b-lactamase have been reported to be
disseminating in Canada [50].
Even when different locales have epidemiolog-
ically similar resistance patterns, the causative
strains may differ in tenacity and linked resi-
stances. The dominant (nosocomial) MRSA
strains in the UK are the ST22 ⁄EMRSA-15 and
ST30 ⁄EMRSA-16 lineages, which, aside from b-
lactams, are resistant only to quinolones and
macrolides. Other nosocomial clones, e.g., the
Iberian type (ST247), are more broadly resistant
[51]; nevertheless, the fitness of the UK strains
may be greater (although this is difficult to prove).
In any event, it is notable that EMRSA-16 has
recently displaced the Iberian clone in the Canary
Islands [52] (Fig. 3), that EMRSA-15 is rapidly
spreading in the Czech Republic [53], and that an
outbreak of EMRSA-16 proved to be exceptionally
costly and difficult to eradicate in Sweden [54].
E. coli strains with CTX-M ESBLs provide a
further example of differences underlying appar-
ent similarity, since they vary in clonality, enzyme
type, and associated resistances. In the UK (and
most of the rest of Europe), most producers have
CTX-M-15 b-lactamase linked to OXA-1, with the
latter conferring resistance to penicillin–b-lacta-
mase inhibitor combinations [55]. In some re-
gions, the producers are substantially clonal in
their population structure; in others, they are
diverse [56]. In Spain, the numerous producers
largely have CTX-M-9 or CTX-M-14 enzymes [57],
are non-clonal, and may be clinically susceptible
to amoxycillin–clavulanate, even in bacteraemia
[58].
Two further examples of important clonal
differences among countries are, first, for pneu-
mococci, and second, for Clostridium difficile. In
the case of pneumococci, the prevalence of differ-
ent serotypes varies with the country, affecting
the potential coverage of the conjugate vaccine
[59], which is directed against the seven serotypes
that dominate and account for most penicillin
resistance in North America. In the case of
C. difficile, hyper-toxin-producing, fluoroquino-
lone-resistant ribotype 027 and 106 strains spread
first in North America, where they were found
to be associated with increased mortality.
Subsequently, these have begun to spread in
Europe [60,61].
CONCLUSION: THE IMPLICATIONS
Resistance varies with country, partly reflecting
efforts concerning infection and prescribing con-
trols, and partly reflecting chance factors such as
whether a particular resistance clone has reached
that location or not. Prescribing reflects underly-
ing cultural attitudes and assumptions, which go
deep into history.
The plethora of resistance surveys should be
read with these caveats in mind, as well as with a
careful consideration of potential sampling bias.
National and international surveys aim primarily
to show large-scale secular trends. If they are to be
taken as benchmarks for reviewing resistance
rates at individual hospitals, then great care
should be taken to compare like with like.
Nevertheless, if local resistance prevalence rates
do appear to be radically different from national
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data, it is legitimate to ask why, especially if the
patient mix is comparable. Is it a reflection of
infection control or antibiotic prescribing policies,
microbiological sampling or testing policies, or
does the difference reflect the local presence and
dissemination of resistance types or strains that
are not nationally prevalent? When we lecture
internationally, we repeatedly hear questions
such as: ‘We have major problems with ceftazi-
dime-resistant Pseudomonas (or another pathogen)
in our ICU; do you think that’s because we use a
lot of cephalosporins?’ The response is always to
ask whether the Pseudomonas is clonal, implying
an infection control problem, or diverse, reflecting
endemicity or repeated selection. It is disturbing
how rarely the answer is known.
Surveillance data usefully guide antibiotic
policy, particularly for empirical treatment, but
care must also be taken to consider the risk-factors
for particular patients: have they had other recent
rounds of antibiotics, or have they been hospita-
lised, making it more likely that they will be
carrying resistant strains? This is critical, consid-
ering the relationship between resistance and
mortality in severe infections [62].
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